Topoisomerase I inhibitor SN-38

Overview

Topoisomerase I inhibitor SN-38 is the active metabolite of irinotecan hydrochloride (CPT-11) and a potent camptothecin-derived anticancer agent. Its primary biological role is inhibition of topoisomerase I, an enzyme required for relieving torsional stress during DNA replication and transcription. By stabilizing the topoisomerase I-DNA cleavage complex, SN-38 promotes DNA damage and cytotoxicity, particularly in rapidly dividing tumor cells.

In oncology research, SN-38 is widely used as a reference compound for irinotecan-based therapy and as a payload in targeted drug-delivery systems, including antibody-drug conjugates and nanocarriers. Recent studies have continued to evaluate its activity in colorectal cancer, lung cancer, and pancreatic ductal adenocarcinoma models, as well as its susceptibility to metabolic inactivation through SN-38 glucuronidation. These investigations place SN-38 at the intersection of DNA-damaging chemotherapy, resistance biology, and precision drug delivery.

Recent Publications Focus

Below is a summary of the newest research publications targeting Topoisomerase I inhibitor SN-38 (sorted by publication date).

• Salt form and phosphate modification of an SN-38-nitrogen mustard conjugate

  • This study designed bifunctional molecules that combine the Topo I inhibitor SN-38 with the alkylating agent nitrogen mustard through a covalent linkage, then further modified the conjugate using salt forms and phosphate ester groups to address water solubility limitations.
  • The work was aimed at improving physicochemical properties while preserving or broadening antitumor activity. The publication specifically emphasizes combined efficacy and an expanded antitumor spectrum as the rationale for this prodrug-oriented design.
  • This line of research reflects a broader strategy in SN-38 development: pairing DNA-damaging mechanisms with formulation or chemical modifications to overcome the intrinsic solubility constraints of the camptothecin scaffold.

• Design, synthesis, and biological evaluation of a hydrophilic 20-O-glycyl ester prodrug of 10-methoxycamptothecin against lung cancer

  • Although the main compound studied was 10-methoxycamptothecin, the paper directly compared its activity with SN-38, noting that the new prodrug MG16 was substantially more active than SN-38 despite a modest reduction in potency relative to the parent 10-methoxycamptothecin.
  • The comparison reinforces SN-38 as a benchmark Topo I inhibitor in camptothecin-based anticancer research and highlights its role as a reference compound in evaluating new hydrophilic prodrug designs for lung cancer.
  • The study context included lung cancer models, supporting the continued use of SN-38 as a comparator in medicinal chemistry programs aimed at improving delivery and efficacy.

• Downregulation of claudin-2 expression and chemoresistance by saquinavir in human lung adenocarcinoma cells

  • This study reported that saquinavir enhanced the cytotoxic effects of multiple anticancer agents, including SN-38, in lung adenocarcinoma cell line-derived spheroids and patient-derived organoids.
  • The use of three-dimensional spheroid models and patient-derived organoids is notable because these systems better approximate tumor architecture and drug response than conventional monolayer cultures.
  • The findings suggest that modulation of claudin-2-associated chemoresistance may improve SN-38 responsiveness in lung adenocarcinoma, supporting combination strategies rather than SN-38 monotherapy.

• Ratiometric Fluorescent Chemosensing for Predicting Response to Irinotecan-Based Therapies in Pancreatic Ductal Adenocarcinoma

  • This publication examined response prediction for irinotecan-based therapies and explicitly referenced SN-38 in the context of treatment correlation analysis.
  • The reported sentence indicates that the observed correlations were not seen with TOPO-1 expression levels, SN-38, or FOLFOX treatment, suggesting that the studied fluorescent chemosensing approach did not align with these variables in the analyzed pancreatic ductal adenocarcinoma context.
  • The work is relevant to SN-38 because it situates the metabolite within irinotecan-based treatment response assessment and underscores the complexity of predicting benefit from Topo I-directed therapy.

• Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling

  • This study investigated the anti-TROP2 antibody-drug conjugate IMMU132, which delivers SN-38 to induce TOP1-mediated DNA damage and cytotoxicity.
  • The publication links SN-38 payload activity to resistance biology in advanced colorectal cancer, with a focus on dual targeting of TROP2 and PERK and suppression of Wnt/β-catenin signaling.
  • The work reinforces the central role of SN-38 as an ADC payload in colorectal cancer and highlights how pathway-level resistance mechanisms can influence the effectiveness of SN-38-based targeted therapy.

• Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions

  • In human liver microsomes, fedratinib exhibited mixed inhibition of SN-38 glucuronidation, with a reported Ki,u value of 0.58 ± 0.13 μM.
  • This finding is pharmacologically important because SN-38 glucuronidation is a key metabolic route affecting exposure, clearance, and toxicity risk. Inhibition of this pathway may increase systemic SN-38 levels and raise the potential for drug-drug interactions.
  • The study places SN-38 in the context of metabolic liability and supports careful consideration of co-administered therapies, including agents such as nirmatrelvir/ritonavir or raltegravir when evaluating interaction risk in broader oncology settings.

• Targeted nanotheranostics mitigates radiation-induced fibrosis to promote immune infiltration and enhance radio-chemotherapy in pancreatic ductal adenocarcinoma

  • This study prepared topoisomerase I inhibitor SN-38-loaded mesoporous silica-coated Bi2O3 nanoparticles (S-MBO NPs) as part of a targeted nanotheranostic strategy.
  • The formulation was designed to mitigate radiation-induced fibrosis, promote immune infiltration, and enhance radio-chemotherapy in pancreatic ductal adenocarcinoma.
  • The use of Bi2O3 nanoparticles and mesoporous silica coating reflects a delivery-focused approach to SN-38, aiming to improve local therapeutic performance and integrate chemotherapy with radiotherapy-related effects in a difficult-to-treat tumor type.

Method PMIDs

• [PMID 41747993]

Target PMIDs

• [PMID 41865567]
• [PMID 41812429]
• [PMID 42081994]
• [PMID 42043185]
• [PMID 42030933]
• [PMID 41455284]